MatthewDHellmannMD

Oncology • New York, NY

Physician

Join to view full profile

Dr. Hellmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hellmann's full profile

Already have an account?

Office
300 E 66th St
New York, NY 10065
Phone+1 617-726-2862

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
Johns Hopkins University School of MedicineClass of 2008

Certifications & Licensure

NY State Medical License 2011 - 2026
NJ State Medical License 2020 - 2023

Clinical Trials

Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies Start of enrollment: 2019 Mar 08
Withdrawn
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Start of enrollment: 2020 Feb 25
Recruiting
Phase 1, Phase 2

Publications & Presentations

PubMed

8 citations
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo
Journal for Immunotherapy of Cancer. 2024-02-02
1431 citations
OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah Fierberg Phillips, Ritika Kundra, Hongxin Zhang
JCO Precision Oncology. 2017-05-16
309 citations
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response crit...
Tricia R. Cottrell, Elizabeth D. Thompson, Patrick M. Forde, Julie E. Stein, Amy S. Duffield
Annals of Oncology. 2018-08-01

Lectures

Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease.
2019 ASCO Annual Meeting - 6/1/2019
A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
Memorial Sloan Kettering Awards and AppointmentsAugust 17th, 2020
The Pershing Square Foundation Awards $3 Million to Innovative SARS-CoV-2 Research ProjectsJuly 7th, 2020
Join now to see all